Literature DB >> 11882730

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

Ross Davidson1, Rodrigo Cavalcanti, James L Brunton, Darrin J Bast, Joyce C S de Azavedo, Pamela Kibsey, Christine Fleming, Donald E Low.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11882730     DOI： 10.1056/NEJMoa012122

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  96 in total

1.  In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Shana M Gunderson; Robert A Hayes; John P Quinn; Larry H Danziger
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

2.  Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae.

Authors:  James H Jorgensen; Sharon A Crawford; M Leticia McElmeel; Cynthia G Whitney
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

3.  Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.

Authors:  V Erard; O Lamy; P-Y Bochud; J Bille; A Cometta; T Calandra
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-15       Impact factor: 3.267

4.  Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae.

Authors:  Luz Balsalobre; María José Ferrándiz; Josefina Liñares; Fe Tubau; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

5.  Moxifloxacin for community-acquired pneumonia.

Authors:  Bart J A Rijnders
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

6.  Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.

Authors:  H J Smith; A M Noreddin; C G Siemens; K N Schurek; J Greisman; C J Hoban; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Regional variations in quinolone use in France and associated factors.

Authors:  A Gallini; F Taboulet; R Bourrel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-29       Impact factor: 3.267

8.  A study of incidence and characteristics of infections in 476 patients from a single center undergoing autologous blood stem cell transplantation.

Authors:  Noemí Puig; Javier de la Rubia; Isidro Jarque; Miguel Salavert; Pau Montesinos; Jaime Sanz; Guillermo Martín; Guillermo Sanz; Susana Cantero; Ignacio Lorenzo; Miguel A Sanz
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

9.  Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.

Authors:  Heather J Smith; Michael Walters; Tamiko Hisanaga; George G Zhanel; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.

Authors:  Philippe Cottagnoud; Marc Pfister; Fernando Acosta; Marianne Cottagnoud; Lukas Flatz; Felix Kühn; Hans-Peter Müller; Armin Stucki
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.